We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > OPKO

News List

Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency drugs.com
January 21, 2022
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued..
BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry prnewswire
June 23, 2021
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers.
EMA validates Pfizer and OPKO’s somatrogon marketing application for review pharmaceutical-business-review
March 04, 2021
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Pfizer and OPKO’s somatrogon, for review.